Synthesis and evaluation of new polyenic compounds as potential PPARs modulators

Area of Science:

• Medicinal Chemistry
• Molecular Pharmacology
• Endocrinology

Background:

• Type 2 diabetes is a metabolic disorder characterized by insulin resistance and hyperglycemia.
• Peroxisome proliferator-activated receptors (PPARs) are key regulators of glucose and lipid metabolism and are targets for diabetes treatment.
• Existing PPAR agonists like rosiglitazone have shown efficacy but also carry safety concerns.

Purpose of the Study:

• To synthesize novel polyenic molecules derived from nipecotic acid and dienol derivatives.
• To evaluate the effect of these novel compounds on the transcriptional activity of PPARs (PPARα, PPARγ).
• To compare the activity of synthesized compounds with known PPAR agonists (rosiglitazone, WY14,643, GW501516).

Main Methods:

• Chemical synthesis of polyenic molecules A, B, and dienol derivatives C.
• Reporter gene assays to measure PPAR transcriptional activity.
• In vitro evaluation of compound efficacy and comparison with reference drugs.

Main Results:

• Several novel compounds were synthesized and characterized.
• Dienol 39 emerged as the most potent compound among those tested.
• Dienol 39 demonstrated significant PPARα response enhancement (similar to WY14,643) and partial agonism at PPARγ (similar to rosiglitazone).

Conclusions:

• Novel polyenic molecules, particularly dienol 39, show promise as potential therapeutic leads for type 2 diabetes.
• Dienol 39's dual activity on PPARα and PPARγ warrants further investigation for its therapeutic potential and safety profile.
• These findings contribute to the development of new drugs targeting PPARs for metabolic diseases.